Gilead Sciences has announced plans to test a once-a-year injection for HIV prevention, which is expected to revolutionize the current treatment landscape. This new injectable medication, known as lenacapavir, has demonstrated a remarkable efficacy rate, reducing the risk of HIV infection by 96% with twice-yearly doses. As global leaders in the HIV response advocate for increased access to long-acting medications, experts herald lenacapavir as a potential game-changer in the fight against AIDS. While the drug is being celebrated as a breakthrough achievement in AIDS prevention, it is important to note that it does not cure HIV, but rather helps to prevent infection. As the world anticipates the rollout of this groundbreaking solution, concerns remain about equitable access and whether those who need it most will receive it.